검색어: insulinfølsomheden (덴마크어 - 영어)

pasireotid påvirkede ikke insulinfølsomheden.
pasireotide did not affect insulin sensitivity.

forbedret metabolisk kontrol kan øge insulinfølsomheden og dermed nedsætte insulinbehovet.
improved metabolic control may result in increased insulin sensitivity, leading to a reduced insulin requirement.

doxazosin forbedrer insulinfølsomheden hos patienter med forringet følsomhed over for insulin.
doxazosin improves insulin sensitivity in patients with impaired sensitivity to insulin.

da nutropinaq kan reducere insulinfølsomheden, skal patienterne overvåges for tegn på glucoseintolerance.
as nutropinaq may reduce insulin sensitivity, patients should be monitored for evidence of glucose intolerance.

- i muskler, ved forøgelse af insulinfølsomheden, forbedring af perifer glucoseoptagelse og
- in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and

en homa analyse viste, at pioglitazon forbedrer beta-cellefunktionen samt øger insulinfølsomheden.
homa analysis shows that pioglitazone improves beta cell function as well as increasing insulin sensitivity.

glycogenolyse-i muskler, ved forøgelse af insulinfølsomheden, forbedring af perifer glucoseoptagelse og
-in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and

en homa-analyse viser, at pioglitazon forbedrer beta-cellefunktionen og øger insulinfølsomheden.
homa analysis shows that pioglitazone improves beta-cell function as well as increasing insulin sensitivity.

i muskler ved at øge insulinfølsomheden og forbedre perifer optagelse og udnyttelse af glucose ved at forhale intestinal absorption af glucose
in muscle, by increasing insulin sensitivity, improving peripheral glucose uptake and utilisation and delay of intestinal glucose absorption.

nutropinaq reducerer insulinfølsomheden; nedsat glucosetolerance blev rapporteret i både de pivotale og understøttende kliniske studier og efter markedsføring.
nutropinaq reduces insulin sensitivity; glucose tolerance impairment was reported in both the pivotal and supportive clinical trials and the post-marketing surveillance survey.

ved i beskedent omfang at forøge insulinfølsomheden, forbedre den perifere glucoseoptagelse og -udnyttelse ved at forsinke den intestinale glucoseabsorption.
by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation; by delaying intestinal glucose absorption.

i muskler, ved forøgelse af insulinfølsomheden, forbedring af perifer glucoseoptagelse og - udnyttelse ved at forsinke den intestinale glucoseabsorption.
in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation by delaying intestinal glucose absorption.

på grund af forbedret metabolisk kontrol og deraf følgende øget insulinfølsomhed kan yderligere dosisjustering blive nødvendig.
with improved metabolic control and resulting increase in insulin sensitivity a further adjustment in dosage regimen may become necessary.